Printer Friendly

Quick-Med Technologies, Inc. and The University of Florida Collaborate to Develop The Next Generation of NIMBUS(TM) Antimicrobial Technology.

GAINESVILLE, Fla. -- Quick-Med Technologies, Inc., (OTCBB:QMDT) ("Quick-Med Technologies" or "QMT"), in collaboration with the University of Florida at Gainesville ("UF") has developed a new generation of the Company's NIMBUS(TM) technology making it significantly more cost-effective and valuable in medical applications.

NIMBUS(TM) is a powerful microbicidal agent that can be permanently bonded to materials such as cotton, cotton blends or polyurethane to create advanced wound dressings, fabrics or other medical or consumer products. The new technology significantly reduces production cost and is highly effective against key strains of bacteria that have become resistant to antibiotics commonly used to treat infections. Importantly, the new technology has been designed to sharply reduce the possibility that any bacteria could develop resistance to the treated articles.

The results are based on six years of research conducted by QMT and UF on new techniques of bonding the Company's NIMBUS(TM) technology to various substrates. Prior test results have shown that this material can kill up to 99.9999% of most bacteria types including those often found on a person's skin, such as Staphylococcus aureus, or Staph., as well as common odor-causing bacteria and the fungus that causes athlete's foot. New tests performed earlier this year by Biological Consulting Services, an independent research laboratory based in Florida, using industry standard test AATCC-100, confirm that the next generation of NIMBUS(TM) kills 99.9999% of MRSA (Methicillin-Resistant Staphylococcus aureus) and VRE (Vancomycin-Resistant Enterococcus), two potentially lethal bacteria strains that have become resistant to traditional antibiotics and are now responsible for many hospital and nursing home infections.

In 1999, MRSA accounted for more than 50 percent of all Staphylococcus aureus infections within U.S. intensive care units (ICU). This proportion increased to more than 60 percent in 2003. VRE rates have continued to increase and now account for more than 25 percent of ICU enterococci infections, according to the National Nosocomial (hospital-acquired) Infections Surveillance system. Mortality rates for VRE bacteremia and sepsis have been reported to exceed 30 percent.(1)

According to The Pennsylvania Healthcare Cost Containment Council ("PHC4") report dated July 2005, Pennsylvania hospitals had 11,668 confirmed hospital-acquired infections in 2004. Further, according to this report, the hospital admissions in which these infections occurred were associated with 1,793 deaths, and an estimated 205,000 extra hospital days and $2 billion in additional hospital charges. These numbers are out of a total of 1.5 million discharges from 173 general acute care hospitals.(2)

Based on current trends, it appears MRSA and VRE will be increasingly problematic, not only in acute care settings, but also in long-term care facilities and the community.

The QMT/UF research team, led by William Toreki III, Ph.D., Senior Polymer Chemist for Quick-Med Technologies, has used the new technology to develop a set of advanced wound dressings that kill bacteria and do not allow the active microbicide to detach and enter the wound. Along with the unique molecular structure of NIMBUS(TM), this property decreases the possibility that bacteria can develop resistance to NIMBUS(TM). Clinical tests of the new material in wound dressing are planned at Shands Hospital at the University of Florida for later this year.

"A focus for the company was to develop a cost-effective dressing that would absorb wound fluid and stop bacteria from growing in the dressing itself. This would prevent larger numbers of bacteria from being shed back onto the wound and reduce the chance of the wound becoming infected," commented Professor Gregory S. Schultz Ph.D., Vice President of Clinical Research & Development of Quick-Med Technologies, and a Professor of Obstetrics and Gynecology at the University of Florida. "Other wound dressings that contain metal microbicides, like silver, or copper ions, also act as bacterial barrier, but these dressings release the microbicidal ions into wound fluid and tissue, and as the concentration of the heavy metal ions decreases in the dressings and wounds, development of resistant bacteria is encouraged."

"Controlling moisture and staving off infection are two of the most important aspects of wound healing," said Jeffrey M. Davidson, Ph.D., President of the Wound Healing Society and Vanderbilt University Professor of Pathology. "Control of infection is very important for any type of wound, bacteria will produce substances that are harmful to the cells around them. They're trying to colonize. They're trying to make a home for themselves."

"The military sector is another potential market for the company. Clothing material that kills athlete's foot fungi could help soldiers in the field who often don't have time to change clothing or shower. Battle field wound dressings are another significant opportunity," said Maj. Gen. George E. Friel (Ret.), Vice President of Chemical & Biological affairs of Quick-Med Technologies.


(1) North Dakota Department of Health - May/June 2004 Epidemiology Report.

(2) PHC4 Research Brief - Issue No. 5 July 2005: Hospital-Acquired Infections in Pennsylvania.


NIMBUS(TM) is comprised of strands of a vast number of microbicidal groups that are permanently bonded to a variety of substrates, including wound dressing, fibers, paper, apparel, and even hospital bedding and gowns. This permanent bond is part of why germs do not develop resistance. Other dressings use a process that allows molecules to diffuse into the wound, which can slow healing and increase the chance that bacteria will develop resistance.

About Quick-Med Technologies, Inc.

Quick-Med Technologies is a life sciences company focused on developing proprietary, broad-based technologies for consumer, industrial, and healthcare use, as well as for advanced military and civilian medical applications. The Company's two core products under development are: (1) MultiStat(TM), a family of advanced compounds shown to be effective in broad-based skin therapy applications; and (2) NIMBUS(TM), a family of advanced polymers that can be used in a wide range of applications from advanced wound care to industrial and consumer preservatives. Quick-Med Technologies is listed under the symbol "QMDT" on the OTC Bulletin Board. For additional information, visit Quick-Med Technologies' website: or email at For Details, Contact: David S. Lerner, President at 561-750-4202. For Investor Relations, Contact: Natasha A. Sorobey at 561-208-8259.

Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology is intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at The development of the above-referenced material by Quick-Med Technologies, Inc. researchers in collaboration with the University of Florida at Gainesville should not be construed by any means as an indication of the present or future value of the Company or its common stock. Additionally, the development of the above-referenced is no assurance that the material will be commercially marketed or that such marketing will be successful. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. Unless otherwise required by applicable law, the Company does not undertake, and it specifically disclaims any obligation, to update any forward looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such a statement.
COPYRIGHT 2005 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005, Gale Group. All rights reserved. Gale Group is a Thomson Corporation Company.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Geographic Code:1USA
Date:Sep 13, 2005
Previous Article:ATI is the Principal Graphics Provider for Microsoft's Professional Developer's Conference.
Next Article:Inovio Biomedical Awarded $1 Million by U.S. Department of Defense for Bioterrorism Collaboration with Leading Army Laboratory.

Related Articles
ADVANCES IN SHELF LIFE TECHNOLOGY FOR THE FOOD INDUSTRY : A guide to new techniques that help extend product shelf life.
Current status of antimicrobial resistance in Taiwan. (Synopsis).
Antimicrobial resistance in Streptococcus pneumoniae, Taiwan. (Synopsis).
Antimicrobial drug use and methicillin-resistant Staphylococcus aureus, Aberdeen, 1996-2000.
Antimicrobial resistance determinants and future control.
Hidden epidemic of macrolide-resistant pneumococci.
Nonprescribed antimicrobial drugs in Latino community, South Carolina.
Impact of statewide program to promote appropriate antimicrobial drug use.
Multidrug-resistant Salmonella Typhimurium in four animal facilities.
Drug-resistant Escherichia coli, rural Idaho.

Terms of use | Privacy policy | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters